Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
CONCLUSION: In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non-transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results.PMID:34730885 | PMC:PMC8596472 | DOI:10.3325/cmj.2021.62.455-63
Source: Croatian Medical Journal - November 3, 2021 Category: General Medicine Authors: Sandra Ba šić-Kinda Karla Mi šura Jakobac Jasminka Sin čić-Petričević Dajana Deak Marijo Vodanovi ć Marinka Jaki ć-Bubalo Zdravko Mitrovi ć Aron Grube šić Barbara Dreta Dubravka Županić Krmek Bo žena Coha Delfa Radi ć-Krišto Igor Aurer Source Type: research

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.
Authors: Griffiths RI, Gleeson ML, Mikhael J, Danese MD Abstract Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and...
Source: Journal of Cancer Epidemiology - November 18, 2014 Category: Epidemiology Tags: J Cancer Epidemiol Source Type: research

Can Immune Thrombocytopenia Be Cured with Medical Therapy?
Semin Thromb HemostDOI: 10.1055/s-0034-1544001Primary immune thrombocytopenia (ITP) in adults often assumes a chronic course that requires persistent monitoring and treatment. Medical therapy has traditionally been viewed as a means of temporarily raising the platelet count with little or no potential to induce long-term platelet responses off treatment. However, several recent studies have tested the hypothesis that intensive medical therapy administered early in the disease course may ameliorate or even cure ITP. In this review, we propose a biological rationale for medical intervention that simultaneously targets the in...
Source: Seminars in Thrombosis and Hemostasis - March 20, 2015 Category: Hematology Authors: Cuker, AdamPrak, Eline T. LuningCines, Douglas B. Source Type: research